CELL ENCAPSULATION COULD ENHANCE ANTIVIRAL VACCINES
Immunotherapy techniques developed in oncology to combat cancerous cells have great potential for fighting viruses. A research team from the University Hospitals of Geneva (HUG) and the University of Geneva (UNIGE), in Switzerland, in collaboration with MaxiVAX, a spinoff of both institutions, developed an innovative technology called « cell encapsulation ». Originally designed to stimulate immunity to fight cancer, the COVID-19 pandemic motivated the scientists to broaden the scope of their technology to test its effectiveness against viruses. The first results of a pre-clinical study are very encouraging and can be discovered in the journal Vaccines.
MaxiVAX and Minaris Regenerative Medicine Enter into a Manufacturing
GENEVA, Switzerland and MUNICH, Germany – Feb 22, 2021 — MaxiVAX SA, a private Swiss clinical-stage biotech company developing novel anti-cancer vaccines, and Minaris Regenerative Medicine GmbH (“Minaris”), a leading contract development and manufacturing service provider for the cell and gene therapy industry, have entered into a manufacturing agreement for MVX-ONCO-2, a cell-based immunotherapy for the treatment of cancers such as chordoma, head and neck, and other solid tumors.
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 880194.
GENEVA STUDY AGAINST SARS-COV-2 GETS UNDERWAY
Geneva University Hospitals (HUG), the University of Geneva (UNIGE), the Infectious Disease Research Centre at Laval University in Quebec (Canada) and MaxiVAX – a Geneva-based company specialising in biotechnology – are working together to develop a SARS-CoV-2 vaccine. This joint research programme aims to create a vaccine combining an immunostimulator and a specific coronavirus target, namely the spike surface protein. This is administered by intradermal injection with the immunostimulator, whose role is to produce an adjuvant capable of stimulating the immune system. It is implanted under the skin via cell encapsulation, a technology that is already undergoing Phase II clinical tests led by HUG in collaboration with MaxiVAX in the area of cancer immunotherapy.
The first pre-clinical tests for perfecting the vaccine will be carried out on mice in the coming weeks. If preliminary tests prove encouraging, a clinical trial could be set up in the near future.
MaxiVAX awarded €2,785,000 European Commission grant and announces successful closing of its Series B 2 round for an amount of CHF 5 million
- MaxiVAX wins grant among 94 projects funded out of 2,015 applications
- Closing of Series B 2 round of CHF 5 million from new and existing investors
- Funds used for Phase 2 cancer programs
MaxiVAX SA, a private Swiss clinical-stage biotech company developing novel anti-cancer vaccines, announced today that it had been awarded a European Commission grant of €2,785,000, thanks to the Horizon 2020 EIC Accelerator Programme.MaxiVAX was among 94 funded projects out of 2,015 applicants, thereby ranking among the top 4% of high-tech companies.
The company also reported the successful closing of a Series B 2 roundof CHF 5 million from new and existing investors, whose continuing support the company is particularly grateful.
MaxiVAX starts Phase 2 study in Switzerland of innovative cancer vaccine in patients with Head & Neck cancer
- Company winner of 2017 CTI Swiss Medtech Award
- US FDA accepted IND in 2018
MaxiVAX SA, a private Swiss clinical-stage biotech company developing novel anti-cancer vaccines, announced today the start of an open label Phase 2 study to evaluate its MVX-ONCO-1 product in 40-45 patients with Head & Neck cancer. The study is being conducted across different sites in Switzerland in collaboration with SAKK, the Swiss Group for Clinical Cancer Research. All enrolled patients will have a confirmed diagnosis of Head and Neck Squamous Carcinoma (HNSCC), stage III/IV in recurrent or metastatic stage and will have failed standard therapy. The primary endpoint is overall survival at 26 weeks.
MaxiVAX appoints T. Scott Johnson, M.D., as new Chairman
Geneva, Switzerland – 14 December, 2017 – MaxiVAX SA, a private Swiss clinical-stage biotech company developing novel anti-cancer vaccines, today announces the appointment of T. Scott Johnson, M.D., as Chairman, following his joining of the Board of Directors in December 2017. Dr Johnson takes over as Chairman from Dr Bernard Mach, co-founder of MaxiVAX, who remains on the Board. Dr Johnson was a Founder of The Medicines Company where he is currently Chief Medical Advisor and Vice President of Business Development. He is also a Founder and General Partner of JSB Partners, L.P., providing specialized investment banking and advisory services to biotechnology and pharmaceutical companies.
MaxiVAX announces that US FDA accepts Investigational New Drug Application
Geneva, Switzerland, 17 July 2018 – MaxiVAX SA, a private Swiss clinical-stage biotech company developing novel anti-cancer vaccines, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application to conduct clinical trials in the US with its product MVX-ONCO-1.
Dimitrios Goundis, PhD, Chief Executive Officer, commented: “The FDA’s acceptance of our IND is a significant milestone for MaxiVAX. This decision validates the product attributes of MVX-ONCO-1, the promise of the preclinical and clinical data, and the quality of our production & control systems. Above all it is testament to the ingenuity and expertise of our team who are determined to make this significant potential cancer therapy available to patients as soon as possible.”
MaxiVAX appoints Scott Johnson as Board Director
Geneva, Switzerland – 14 December, 2017 – MaxiVAX SA, a private Swiss clinical-stage biotech company developing novel anti-cancer vaccines, today announces the appointment of T. Scott Johnson, M.D., as a Board Director. Dr Johnson was a Founder of The Medicines Company where he is currently Chief Medical Advisor and Vice President of Business Development. He is also a Founder and General Partner of JSB Partners, L.P., providing specialized investment banking and advisory services to biotechnology and pharmaceutical companies.
MaxiVAX appoints Antonio Perez as Chief Medical Officer
Geneva, Switzerland – 14 December, 2017 – MaxiVAX SA, a private Swiss clinical-stage biotech company developing novel anti-cancer vaccines, today announces the appointment of Antonio Perez MD Ph.D., as its Chief Medical Officer. He joins the company after holding senior medical positions at Novartis, Biogen Idec, Basilea, Almirall and Esteve. He has also been a medical advisor to many companies across Europe and the US.
MaxiVAX wins 2017 CTI Swiss Medtech Award
The 2017 CTI Swiss Medtech Award, presented at the Swiss Medtech Day on 13 June, has gone to the biotech company MaxiVAX. MaxiVAX and the Geneva University Hospitals received the CHF 15,000 prize for developing a new vaccine designed to help the immune system in cancer patients fight their own tumor cells. The award was presented by Federal Councillor Johann N. Schneider-Ammann before around 600 guests in the Kursaal, Bern.
Download the poster.
MaxiVAX is 1 of 3 companies nominated to receive the CTI Swiss Medtech Award 2017. The winner announcement and Award ceremony will be held in Bern during the Swiss Medtech Day, on June 13th 2017.
MaxiVAX is presenting the final data of the primary endpoint of its First-In-Man study at the ESMO 2016 congress in Copenhagen.
See the poster.
MaxiVAX announces promising results from its phase 1 anti-cancer clinical trial
Read the full press release.
Press Release: MaxiVAX appoints Dimitrios Goundis as Chief Executive Officer
Read the full press release
Poster Cell-based immunotherapy combining encapsulation cell technology and irradiated autologous tumor cells: A novel technology platform that is both safe and feasible. Results from MVX-ONCO-1 first-in-man Phase 1 Trial.
MaxiVAX will participate in the Bio-Europe 2015 conference, Munich, Germany, Nov 2-4, 2015
MVX-ONCO-1: First in man, Phase I clinical trial combining encapsulation cell technology and irradiated autologous tumor cells for personalized cell-based immunotherapy. Safety, feasibility and clinical outcome results » has been selected by the 18th ECCO – 40th ESMO European Cancer Congress Scientific Committee as a Poster in the poster session « Immunotherapy of Cancer » on 26 September 2015 from 16:45 to 18:45 in Hall C. The poster has also been selected for a new special session called Poster Spotlight from 17:15 to 18:15.